PriceTargets.com logo

aTyr Pharma - ATYR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.67
  • Forecasted Upside: 3,001.34%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.83 As of 03/19/2026 05:00 PM ET
▲ +0.0126 (1.55%)

This chart shows the closing price for ATYR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New aTyr Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATYR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATYR

Analyst Price Target is $25.67
▲ +3,001.34% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is $25.67, with a high forecast of $35.00 and a low forecast of $17.00. The average price target represents a 3,001.34% upside from the last price of $0.83.

This chart shows the closing price for ATYR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in aTyr Pharma. This rating has held steady since August 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/6/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/19/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/15/2025JonesTradingDowngradeStrong-Buy ➝ Hold
9/15/2025Leerink PartnersDowngradeStrong-Buy ➝ Hold
9/15/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight
9/15/2025HC WainwrightDowngradeBuy ➝ Neutral
9/15/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform
9/15/2025Cantor FitzgeraldDowngradeOverweight ➝ Neutral
8/22/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$9.00 ➝ $17.00
6/20/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00
5/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/18/2025Leerink PartnersUpgradeStrong-Buy
2/18/2025Leerink PartnersInitiated CoverageOutperform$16.00
1/6/2025Cantor FitzgeraldInitiated CoverageOverweight
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
12/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
10/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
10/4/2024Wells Fargo & CompanyInitiated CoverageOverweight$17.00
9/5/2024Jefferies Financial GroupInitiated CoverageBuy$9.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
8/14/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$16.00 ➝ $16.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
7/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
(Data available from 3/20/2021 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2025
  • 2 very positive mentions
  • 29 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2025
  • 1 very positive mentions
  • 64 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
10/21/2025
  • 0 very positive mentions
  • 114 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2025
  • 1 very positive mentions
  • 64 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/20/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

aTyr Pharma logo
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.83
Low: $0.79
High: $0.84

50 Day Range

MA: $0.86
Low: $0.67
High: $1.05

52 Week Range

Now: $0.83
Low: $0.64
High: $7.29

Volume

1,049,147 shs

Average Volume

1,296,701 shs

Market Capitalization

$81.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of aTyr Pharma?

The following Wall Street research analysts have issued research reports on aTyr Pharma in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JonesTrading, Leerink Partners, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for ATYR.

What is the current price target for aTyr Pharma?

0 Wall Street analysts have set twelve-month price targets for aTyr Pharma in the last year. Their average twelve-month price target is $25.67, suggesting a possible upside of 3,001.3%. HC Wainwright has the highest price target set, predicting ATYR will reach $35.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $17.00 for aTyr Pharma in the next year.
View the latest price targets for ATYR.

What is the current consensus analyst rating for aTyr Pharma?

aTyr Pharma currently has 1 sell rating, 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATYR, but not buy more shares or sell existing shares.
View the latest ratings for ATYR.

What other companies compete with aTyr Pharma?

Other companies that are similar to aTyr Pharma include Neurogene, Bicycle Therapeutics, Immuneering, I-Mab and Evolus. Learn More about companies similar to aTyr Pharma.

How do I contact aTyr Pharma's investor relations team?

aTyr Pharma's physical mailing address is 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121. The company's listed phone number is (858) 731-8389 and its investor relations email address is [email protected]. The official website for aTyr Pharma is atyrpharma.com. Learn More about contacing aTyr Pharma investor relations.